November 14, 2018
BMC via IV Infusion

Considerations On the Regulatory Status of IV Administration of BMC: A Useful Shot in the Arm? Part Two

In the previous post, I reviewed the risk-based approach the FDA is taking in dealing with the free-for-all that currently exists in the world of regenerative medical therapies, like BMC and PRP. Actually, PRP and BMC don’t seem to raise red flags with the FDA, unlike amniotic fluid, cord blood-based products, fat-derived SVF in orthopedic...
Read More